MARKET

LEXX

LEXX

Lexaria Bioscience Corp
NASDAQ
2.450
+0.010
+0.41%
After Hours: 2.450 0 0.00% 16:49 09/30 EDT
OPEN
2.420
PREV CLOSE
2.440
HIGH
2.590
LOW
2.420
VOLUME
6.07K
TURNOVER
0
52 WEEK HIGH
7.15
52 WEEK LOW
1.850
MARKET CAP
14.58M
P/E (TTM)
-2.0281
1D
5D
1M
3M
1Y
5Y
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields 'Remarkable' Results
New York, New York--(Newsfile Corp. - September 20, 2022) - PCG Digital - Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, Dehyd...
Newsfile · 09/20 12:30
Lexaria Receives New Patent in Mexico
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recognition with the receipt of its 27th worldwide ...
ACCESSWIRE · 08/31 13:05
Lexaria Bioscience Gets Mexican Patent; Shares Higher
Lexaria Bioscience Gets Mexican Patent; Shares Higher
MT Newswires · 08/31 11:19
Lexaria Discusses Valuation Metrics for Biotech Industry
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following information to its stakeholders as an aid to conveniently researching and understanding various non...
ACCESSWIRE · 08/11 13:15
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To hear the AudioPressRelease, please visit: The NetworkNewsAu...
GlobeNewswire · 08/11 12:30
Lexaria Bioscience' Tech Processed Cannabidiol Receives Positive FDA Feedback For Hypertension
Lexaria Bioscience Corp (NASDAQ: LEXX) has received a positive full written response from the FDA from its pre-Investigational New Drug (Pre-IND) meeting regarding DehydraTECH-CBD for hypertension. The FDA confirmed that it agreed with Lexaria's proposal t...
Benzinga · 08/10 14:36
Lexaria announces FDA response on plans for blood pressure drug
Lexaria Bioscience (NASDAQ:LEXX), the developer of Dehyd...
Seekingalpha · 08/10 13:36
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that it has received a positive full written response from the Food and Drug Administration ("FDA") from...
ACCESSWIRE · 08/10 12:15
More
About LEXX
Lexaria Bioscience Corp. is a Canada-based global innovator in drug delivery platforms. The Company’s patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting oral delivery. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company operates through two segments: Intellectual Property and Products.

Webull offers kinds of Lexaria Bioscience Corp stock information, including NASDAQ:LEXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEXX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LEXX stock methods without spending real money on the virtual paper trading platform.